Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00095316 · ClinicalTrials.gov registry record · Phase 3
Caspofungin Study for Fungal Infections in Adults in Critical Care Settings
A Phase 3 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Terminated
- Registry status
- Phase 3
- Development phase
- 1,200
- Enrollment target
NCT00095316 is a Phase 3 study that was terminated before completion, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 1,200 participants.
The verdict
NCT00095316, a Phase 3 study, was terminated before completion, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 1,200 participants
- Enrollment target
Study Summary
Adults admitted to intensive care units are at risk for a variety of complications. One of the most frequent complications is the development of new infections. Infections due to a fungus called Candida are of particular concern. This study will test the possibility that caspofungin, a new therapy for fungal infections, may reduce the rate of Candida infections in subjects at risk.
Interventions
- OTHER Placebo
- DRUG Caspofungin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,200 participants |
| Start Date | 2004-10 |
| Est. Completion | 2006-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00095316
The ClinicalTrials.gov registry entry for NCT00095316 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 1,200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00095316 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00095316 about?
NCT00095316 is a clinical study titled "Caspofungin Study for Fungal Infections in Adults in Critical Care Settings". Adults admitted to intensive care units are at risk for a variety of complications. One of the most frequent complications is the development of new infections. Infections due to a fungus called Candida are of particular concern. This study will test the possibility that caspofungin, a new therapy f...
What is the current status of trial NCT00095316?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 1,200 participants. The study started on 2004-10. Estimated completion is 2006-09.
What interventions are being tested in trial NCT00095316?
The interventions under investigation include: Placebo (OTHER), Caspofungin (DRUG).
Who is sponsoring clinical trial NCT00095316?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.